Hostname: page-component-77f85d65b8-6c7dr Total loading time: 0 Render date: 2026-04-17T09:57:30.776Z Has data issue: false hasContentIssue false
  • English
  • Français

Addressing High Drug Prices by Reforming Pharmacy Benefit Managers

Published online by Cambridge University Press:  04 March 2024

Benjamin N. Rome Open the ORCID record for Benjamin N. Rome [Opens in a new window]
Get access Rights & Permissions [Opens in a new window]

Abstract

Recently, Congress has focused on reforms to address pharmacy benefit managers’ (PBMs) role in high drug prices for patients. Congress must not excessively restrict PBMs’ ability to negotiate with manufacturers; alternatively, reforms could be paired with other policies that address the high prices of brand-name drugs.

Keywords

Prescription Drug PricesPharmacy Benefit ManagersManufacturer RebatesHealth PolicyCongressional Reform

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Hamel, L. et al., Public Opinion on Prescription Drugs and Their Prices (October 20, 2022), KFF, available at <https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices/> (last visited May 11, 2023).+(last+visited+May+11,+2023).>Google Scholar
Dusetzina, S.B. et al., “Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions,” Health Affairs 41, no. 4 (2022): 487–496, available at <https://www.healthaffairs.org/doi/10.1377/hlthaff.2021.01742> (last visited November 26, 2023).CrossRefGoogle ScholarPubMed
Rome, B.N. et al., “Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study,” American Heart Journal 233 (2021), available at <https://www.sciencedirect.com/science/article/abs/pii/S0002870320304129> (last visited November 26, 2023); U.R. Essien et al., Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes, JAMA Network Open, available at <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805466> (last visited November 26, 2023).Google ScholarPubMed
Hwang, T.J., Kesselheim, A.S., and Rome, B.N., “New Reforms to Prescription Drug Pricing in the U.S.: Opportunities and Challenges,” JAMA 328, no. 11 (2022): 1041–1042, available at <https://jamanetwork.com/journals/jama/article-abstract/2795651> (last visited November 26, 2023).Google ScholarPubMed
Cai, C. and Rome, B.N., “Reforming Pharmacy Benefit Managers — A Review of Bipartisan Legislation,” New England Journal of Medicine 389 (2023): 1640–1643, available at <https://www.nejm.org/doi/full/10.1056/NEJMp2309533> (last visited January 17, 2024).Google ScholarPubMed
Van de Wiele, V.L., Kesselheim, A.S., and Sarpatwari, A., “Barriers To U.S. Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation,” Health Affairs 40, no. 8 (2021): 1198–1205, available at <https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.02484> (last visited November 26, 2023). Article examines barriers to U.S. biosimilar market growth.CrossRefGoogle ScholarPubMed
Rome, B.N., Lee, C.Y., and Kesselheim, A.S., “Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012–2018,” Clinical Pharmacology and Therapeutics (2020): 1–5, <available at https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1983> (last visited November 26, 2023).Google ScholarPubMed
Kesselheim, A.S., Avorn, J., and Sarpatwari, A., “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316, no. 8 (2016): 858–871.CrossRefGoogle ScholarPubMed
Rome, B.N., Egilman, A.C., and Kesselheim, A.S., “Trends in Prescription Drug Launch Prices, 2008-2021,” JAMA 327, no. 21 (2022): 2145–2147.CrossRefGoogle ScholarPubMed
Hernandez, I. et al., “Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the U.S., 2007-2018,” JAMA 323, no. 9 (2020): 854.CrossRefGoogle ScholarPubMed
Committee on Oversight and Reform, U.S. House of Representatives, Drug Pricing Investigation: AbbVie—Humira and Imbruvica, 2021, available at <https://oversightdemocrats.house.gov/sites/democrats.oversight.house.gov/files/Committee%20on%20Oversight%20and%20Reform%20-%20AbbVie%20Staff%20Report.pdf> (last visited March 15, 2023).+(last+visited+March+15,+2023).>Google Scholar
Emanuel, E.J. et al., “Drug reimbursement regulation in 6 peer countries,” JAMA Internal Medicine 180, no. 11 (2020): 1510–1517; L.Z. Rand and A.S. Kesselheim, “An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles,” Journal of Law, Medicine and Ethics 48, no. 3 (2020): 583–594.CrossRefGoogle ScholarPubMed
Mulcahy, A.W. et al., International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies, RAND Corporation, 2021, available at <https://doi.org/10.7249/RR2956>..>Google Scholar
See T.J. Huang, supra note 4.Google Scholar
Dave, C.V., Hartzema, A. and Kesselheim, A.S., “Prices of Generic Drugs Associated with Numbers of Manufacturers,” New England Journal of Medicine 377, no. 26 (2017): 2597—2598.Google ScholarPubMed
Rome, B.N., Sarpatwari, A., and Kesselheim, A.S., “State Laws and Generic Substitution in the Year After New Generic Competition,” Value in Health 25, no. 10 (2022): 1736–1742; C.A. Sacks et al., “Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions,” JAMA Internal Medicine 181, no. 1 (2021): 16–22.CrossRefGoogle ScholarPubMed
Congressional Budget Office, Prescription Drugs: Spending, Use, and Prices. (2022), available at <https://www.cbo.gov/publication/57772> (last visited June 1, 2022): at 222–229.+(last+visited+June+1,+2022):+at+222–229.>Google Scholar
Conrad, R. et al., U.S. Food and Drug Administration, Estimating Cost Savings From Generic Drug Approvals In 2017 (2017), available at <https://fda.report/media/113500/Estimating-Cost-Savings-From-Generic-Drug-Approvals-In-2017.pdf> (last visited April 12, 2022).+(last+visited+April+12,+2022).>Google Scholar
Kesselheim, A.S., Avorn, J., and Sarpatwari, A., “Strategies That Delay Market Entry of Generic Drugs,” JAMA Internal Medicine 177, no. 11 (2017): 1665–1669.Google Scholar
Carrier, M.A. and Shadowen, S.D., “Product hopping: A new framework,” Notre Dame Law Review 92, no. 1 (2016): 167–230.Google Scholar
Rome, B.N., Tessema, F.A., and Kesselheim, A.S., “U.S. Spending Associated with Transition from Daily to 3-Times-Weekly Glatiramer Acetate,” JAMA Internal Medicine 180, no. 9 (2020): 1165–1172.Google ScholarPubMed
22. 2022 Employer Health Benefits Survey - Section 9: Prescription Drug Benefits (October 27, 2022), KFF, available at <https://www.kff.org/report-section/ehbs-2022-section-9-prescription-drug-benefits/> (last visited May 24, 2023).+(last+visited+May+24,+2023).>Google Scholar
Naci, H. et al., Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D (February 24, 2023), JAMA Health Forum, available at <https://jamanetwork.com/journals/jama-health-forum/fullarticle/2801780> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar
Howell, S., Yin, P.T., and Robinson, J.C., “Quantifying The Economic Burden Of Drug Utilization Management On Payers, Manufacturers, Physicians, And Patients,” Health Affairs 40, no. 8 (2021): 1206–1214.Google ScholarPubMed
Dusetzina, S.B. and Bach, P.B., “Prescription Drugs — List Price, Net Price, and the Rebate Caught in the Middle,” JAMA 321, no. 16 (2019): 1563–1564.Google ScholarPubMed
Rome, B.N. et al., Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs (May 4, 2021), JAMA Network Open, available at <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779442> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar
Feldman, W.B. et al., Estimating Rebates and Other Discounts Received by Medicare Part D (June 4, 2021), JAMA Health Forum, available at <https://jamanetwork.com/journals/jama-health-forum/fullarticle/2780805> (last visited November 26, 2023)+(last+visited+November+26,+2023)>Google Scholar
Grassley, Wyden Release Insulin Investigation, Uncovering Business Practices Between Drug Companies and PBMs That Keep Prices High (January 14, 2021), United States Senate Committee on Finance, available at <https://www.finance.senate.gov/chairmans-news/grassley-wyden-release-insulin-investigation-uncovering-business-practices-between-drug-companies-and-pbms-that-keep-prices-high> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Hwang, T.J. et al., “Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017,” JAMA 322: 267–269.Google Scholar
Medicare Payment Advisory Commission (MedPAC), July 2023 Data Book, Section 10: Prescription Drugs. (2023), available at <https://www.medpac.gov/wp-content/uploads/2023/07/July2023_MedPAC_DataBook_Sec10_SEC.pdf> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Center for Improving Value in Health Care (CIVHC), Colorado Prescription Drug Spending and the Impact of Drug Rebates. (2021), available at <https://civhc.org/wp-content/uploads/2021/01/CO-Drug-Rebate-Report_1.8.2020.pdf >(last visited August 28, 2023).(last+visited+August+28,+2023).>Google Scholar
Fein, A.J., The Top Pharmacy Benefit Managers of 2021: The Big Get Even Bigger (April 5, 2022), Drug Channels, available at <https://www.drugchannels.net/2022/04/the-top-pharmacy-benefit-managers-of.html> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Yost, D., Ohio Auditor of State, Ohio’s Medicaid Managed Care Pharmacy Services: Auditor of State Report (2018), available at <https://ohioauditor.gov/auditsearch/Reports/2018/Medicaid_Pharmacy_Services_2018_Franklin.pdf> (last visited May 14, 2023).+(last+visited+May+14,+2023).>Google Scholar
Fein, A.J., Ph.D., Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A May 2023 Update (May 10, 2023), Drug Channels, available at <https://www.drugchannels.net/2023/05/mapping-vertical-integration-of.html> (last visited May 13, 2023).+(last+visited+May+13,+2023).>Google Scholar
Sunshine in the Black Box of Pharmacy Benefit Management: Florida Medicaid Pharmacy Claims Analysis (2020), 3Axis Advisors, available at <https://static1.squarespace.com/static/5c326d5596e76f58ee234632/t/5e384f26fc490b221da7ced1/1580748598035/FL+Master+Final+Download.pdf> (last visited May 13, 2023).+(last+visited+May+13,+2023).>Google Scholar
Lalani, H.S., Kesselheim, A.S., and Rome, B.N., “Potential Medicare Part D Savings on Generic Drugs from the Mark Cuban Cost Plus Drug Company,” Annals of Internal Medicine 175, no. 7 (2022): 1053–1055.CrossRefGoogle Scholar
Trish, E. et al., “Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members,” JAMA Internal Medicine 181 no. 10 (2021): 1414–1416.Google ScholarPubMed
Cole, B.A.L. and Dusetzina, S.B., “Generic Price Competition for Specialty Drugs: Too Little, Too Late?” Health Affairs 37, no. 5 (2018): 738–742.CrossRefGoogle ScholarPubMed
Senate Finance Committee Leaders Praise Committee Passage of Legislation to Help Lower Prescription Drug Costs (August 11, 2023), U.S. Senate Committee on Finance, available at <https://www.finance.senate.gov/chairmans-news/senate-finance-committee-leaders-praise-committee-passage-of-legislation-to-help-lower-prescription-drug-costs> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Aitken, M. and Kleinrock, M., Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023 (May 9, 2019), IQVIA, available at <https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar